HUTIGMD@EC2705A

CLSA Downgrades Taikang Medicine's 2027 Earnings Forecast and Target Price

HSBC Raises Target Price and Rating for Tigermed

Goldman Sachs Raises Target Price for Tigermed to HKD 66.4 and Maintains Buy Rating

UBS Analyzes Taikang Medicine's 2025 Earnings Forecast

Taigemedicine anticipates a 105%-204% increase in net profit for 2025

Citi Initiates 90-Day Upside Catalyst Observation on Tigermed

CLSA Raises Target Price for Tigermed to HKD 57.2 and Reiterates Rating

CITIC Securities Fund Reduced 216,800 Shares of Taege 医药

JPMorgan Cuts Stake in 泰格医药 by 831,247 Shares

JPMorgan Increases Stake in Therapix Biosciences to 8.39%

Cao Xiaochun Completes Share Reduction Plan at Theragen Medical

HSBC Analyst Reiterates Buy Rating on TG Therapeutics H-Shares

CLSA Maintains Tigermed's 'Outperform' Rating and Adjusts Target Price and Profit Projections

Tiger Medicine Reports 98.73% YoY Growth in Net Profit for Q3

TIGERMED released FY2025 Q3 earnings on October 28 Pre-Market (BJT), actual revenue HKD 1.941 B (forecast HKD 1.914 B), actual EPS HKD 0.8016 (forecast HKD 0.4808)

TIGERMED released FY2025 9 Months earnings on October 28 Pre-Market (BJT), actual revenue HKD 5.462 B, actual EPS HKD 1.2914

E Fund Management Co. cuts holdings of 泰格医药 by 429,800 shares

E Fund Management Increases Holdings in TherapuTech by 573,100 Shares

Hangzhou 泰格 Pharma Consulting Co., Ltd Holds Third Quarter Financial Report Review Meeting

TIGERMED to Release FY2025 Q3 Earnings on October 22 Pre-Market (BJT), Forecast Revenue HKD 1.946 B, EPS HKD 0.4808

KO YO GROUP

SOFTMEDX

HUAZHANG TECH

SANERGY GROUP

GEOTECH HLDGS

YUNKANG GROUP

CHINA INFO TECH

AGTECH HOLDINGS

PUTIAN COMM

MODERN LAND

516500

516820

03347

159837

159849

513290

300347

516930

HSBC's research report indicates that Tigermed's revenue and recurring net profit forecasts for last year exceeded expectations, with new order amounts ranging from RMB 9.5 billion to 10.5 billion, representing a year-on-year growth of 18.7%. The bank has raised its revenue forecast for 2026 to 2027 by 7%, but lowered its recurring net profit forecast by 1% to 3%. It maintains a "Buy" rating and raises the target price from HKD 59 to HKD 64.6, expecting the company's business recovery trend to continue

AASTOCKS

ChinaAMC CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

TIGERMED

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Tigermed

Minsheng Royal CSI Biotechnology Theme ETF

The research report "Big Banks" raised the target price of Tigermed to 64.6 yuan, with last year's revenue and new orders exceeding expectations

Hangzhou Tigermed Consulting Co. Ltd. will hold an extraordinary general meeting on March 5, 2026, to vote on changes to its registered company address and related amendments to its articles of association. The board recommends shareholders vote in favor of this proposal.

Reuters

Abstimmung über Änderung der Satzung und Firmenadresse bei Hangzhou Tigermed Consulting Co. Ltd

01969

09887

01396

06869

01651

00336

01797

09901

01729

CHINA CHUNLAI(01969) rose 22.76%, with a trading turnover 1.4 Billion HKD, and a year-to-date rose 7.9%. LEADS BIOLABS-B(09887) rose 10.77%, with a trading turnover 89.1 Million HKD, and a year-to-date rose 31.1%. TIGERMED(03347) rose 8.24%, with a trading turnover 388.0 Million HKD, and a year-to-date rose 29.8%.

Top Gainers & Losers

CHINA CHUNLAI

LEADS BIOLABS-B

GD-HKGBA HLDGS

YOFC

TSUGAMI CHINA

HUABAO INTL

EAST BUY

NEW ORIENTAL-S

TIME INTERCON

Top 10 HK Stock Gainers (1.30)

UBS released a research report indicating that TIGERMED's revenue for the fiscal year 2025 is expected to grow by 1% to 16%, but the net profit attributable to shareholders is expected to be between RMB 830 million and RMB 1.23 billion, which is below expectations. The company stated that the prices of newly signed orders are stabilizing but still declining, affecting profit margins. UBS is paying attention to signals of a recovery in the prices of newly signed orders in 2026 and has set a target price of HKD 57.1 with a "Buy" rating

UBS: TIGERMED's net profit last year was below expectations, focus on the recovery of new order prices this year

Tigermed expects its profit for the fiscal year 2025 to grow by 105%-204%, ranging from 830 million to 1.23 billion RMB. The company's disposal and income from non-current financial assets have significantly increased, with both the number and amount of new orders showing growth. The total net new orders for the year are expected to be between 9.5 billion and 10.5 billion RMB, and operating revenue is projected to be between 6.66 billion and 7.68 billion RMB, an increase of 1%-16%

"Profit Alert" Tigermed forecasts a profit increase of 105%-204% last year

Hangzhou Tigermed Consulting Co., Ltd. (HK:3347) forecasts a significant increase in its 2025 net profit, estimating between RMB830 million and RMB1.23 billion, a rise of 105% to 204% year-on-year. This growth is attributed to non-recurring gains estimated at RMB500 million to RMB740 million, contrasting with a loss of RMB449.8 million last year. However, underlying net profit is expected to decline by 43% to 61%. The stock currently holds a Hold rating with a price target of HK$54.00.

Tip Ranks

Tigermed Forecasts Surging 2025 Profit on Large Non-Recurring Gains

Hangzhou Tigermed Consulting Co. Ltd. expects its net profit for 2025 to be between RMB 830 million and RMB 1.23 billion, marking a 105% to 204% increase from RMB 405.1 million in 2024. This surge is mainly due to a rise in non-recurring gains, despite a decline in average unit prices of new orders. The final audited results will be published in the 2025 annual report.

Tigermed Projects Over 50% Surge in 2025 Net Profit

The US imposed a 39% tariff on imported gold bars, sparking a rally in gold stocks, with Lao Feng Xiang rising nearly 4% again. The semiconductor sector was dragged down by SMIC's Q2 net profit plunging 19%, with most stocks falling.

SMIC

SMIC HK SDR 5to1

LAOPU GOLD

ZIJIN MINING

Zijin Mining

SD GOLD

SD-GOLD

FORTIOR

Asymchem

ZHAOJIN MINING

HORIZONROBOT-W

HENGRUI PHARMA

Hengrui Pharma

LINGBAO GOLD

INNOSCIENCE

CE HUADA TECH

BATELAB

ZAI LAB

Zai Lab

FRONTAGE

CHIFENG GOLD

TONGGUAN GOLD

CHI SILVER GP

HUA HONG SEMI

Hua Hong

Hot Trades in Hong Kong Stocks (8.8)｜Gold Sector Rises Across the Board on Tariff Catalysts, SMIC Leads Decline by 6%

Hot trading industry trends on August 7 and related Hong Kong semiconductor stocks. Hong Kong semiconductor stocks opened lower in early trading but then surged strongly, with Innoscience gaining over 11%, and industry leader SMIC rising over 3%. Core logic: On the news front, on August 1, Innoscience officially responded to rumors of collaboration with NVIDIA. The announcement stated that the company has recently partnered with global AI technology leader NVIDIA to jointly promote the large-scale implementation of the 800VDC (800-volt direct current) power architecture in AI data centers. Clear signals of a cyclical bottom: Global semiconductor inventory reduction is nearing its end...

NVIDIA

SJM HOLDINGS

MGM CHINA

FIT HON TENG

WUXI APPTEC

WuXi AppTec

INNOCARE

InnoCare Pharma

XIAOMI-W

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

GALAXY ENT

Galaxy Entertainment Group

NAGACORP

WYNN MACAU

MELCO INT'L DEV

SANDS CHINA LTD

Sands China

CSPC PHARMA

INNOVENT BIO

COWELL

SHANGHAI FUDAN

FMSH

SOLOMON SYSTECH

Apple

Hot Trades in Hong Kong Stocks (8.7)｜ Chip Stocks Rebound Strongly, Apple Supply Chain Follows; Xiaomi and Pharmaceuticals Retreat Under Pressure

HUTIGMD@EC2705A(23725.HK)

The research report "Big Banks" raised the target price of Tigermed to 64.6 yuan, with last year's revenue and new orders exceeding expectations

Abstimmung über Änderung der Satzung und Firmenadresse bei Hangzhou Tigermed Consulting Co. Ltd

Top 10 HK Stock Gainers (1.30)

UBS: TIGERMED's net profit last year was below expectations, focus on the recovery of new order prices this year

"Profit Alert" Tigermed forecasts a profit increase of 105%-204% last year